Back to top


Neuroblastoma is the most common solid tumour during the first 2 years of life

It originates in the peripheral nervous system, and its prognosis is highly variable, depending on the characteristics of each case.

At SJD Barcelona Children's Hospital, we perform a molecular evaluation of the tumour that allows us to determine which patients need to undergo an aggressive treatment after surgery and which do not.

Treatment of neuroblastoma in Spain

We are one of the few centres in Europe that offers anti-GD2 immunotherapy treatment. This treatment increases survival in patients with high-risk neuroblastoma by 20%.


Among patients with high-risk neuroblastoma treated at our centre, 68% are disease-free at 3 years.


In studies in vitro and in mice, we have discovered that a medicine approved for metabolic diseases inhibits neuroblastoma growth and aggressiveness. We have designed a clinical trial in patients.

Immunotherapy, the treatment for Ivan’s neuroblastoma

The Barysiuk family’s story is one of triumph. Before arriving at SJD Barcelona Children’s Hospital, they overcame a series of obstacles which finally enabled their son to access cancer treatment. Our hospital is the only one in Europe that offers anti-gd2 immunotherapy, which is sought after by patients and families from many countries. Iván had undergone an operation for a neuroblastoma in Belarus and he was a potential candidate to receive this therapy. Don’t miss the real story of how this brave little boy and his family were be able to access biological therapy.

The SJD Barcelona Children's Hospital's Oncology and Haematology Department

The SJD Barcelona Children's Hospital's Oncology and Haematology Department is the national reference centre of for the treatment of developmental cancer and an international reference centre for determined types of tumours.